Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Apnimed (NASDAQ:APMD) with a Overweight rating and announces Price Target of $60.